Boston scientific announces agreement to acquire intera oncology® inc.

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases marlborough, mass. , nov. 25, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has entered into a definitive agreement to acquire intera oncology® inc., a privately held medical device company that provides the intera 3000 hepatic artery infusion pump and floxuridine – a chemotherapy drug – both of which are approved by the u.s. food and drug administration.
BSX Ratings Summary
BSX Quant Ranking